Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 309.00
Ask: 310.00
Change: 10.00 (3.33%)
Spread: 1.00 (0.324%)
Open: 304.00
High: 316.00
Low: 304.00
Prev. Close: 300.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Tue, 09th Jun 2020 13:25

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Venture Life Group PLC - Berkshire-based self care products maker - Says order book "significantly ahead" of year prior. Reports solid demand for hand sanitiser gel product. Extends relationship with Alliance Pharma, becoming second manufacturer of Wiltshire-based pharmaceutical firm's Kelo-Cote scar gel products.

----------

Better Capital PCC Ltd - Guernsey-based investment company - To take write-down on valuation of investment in Everest, a British windows and home improvement firm. Better Capital's Fund II has invested GBP3.2 million into creation of Everest 2020, which bought assets of Everest Ltd, including its order pipeline. Pre-packaged administration deal rescued over 400 jobs at Everest and ensures existing orders can be completed.

----------

Plaza Centers NV - Netherlands-based property firm - Says buyer of company's stake in a shopping and entertainment centre in Belgrade will pay firm EUR830,000 to settle purchase. Plaza Centers to increase amount paid to bondholders to EUR500,000 from EUR250,000 at next payment date on July 1.

----------

Altyn PLC - gold miner in Kazakhstan - Says "positive momentum" continuing in second quarter with annualised monthly production run rate of 600,000 tonnes per year achieved in April and May. Altyn adds this represents 60% growth quarter-on-quarter. Altyn explains gold recovery grades also improved and beating budgeted targets. Seeing pick up in interest among investors, so far raised USD3.2 million out of USD10 million maximum in Astana Stock Exchange bond issue.

----------

Ormonde Mining PLC - Spain-focused natural resources - Cost-effective work programme at existing Spanish gold assets being advanced. Continuing to assess prospective projects, with 100 reviewed to date and a handful shortlisted "for further active consideration".

----------

Chaarat Gold Holdings Ltd - Gold miner in Armenia and Kyrgyz Republic - Targets 300,000 ounces per year production from 2026 at Kyzyltash deposit, Kyrgyz Republic. Lays out plans to get there, beginning with updated feasibility study in 2022, project financing in 2023 before construction follows in 2024 and 2025.

----------

Rockfire Resources PLC - Australia-focused gold and copper explorer - Reports results of 3D magnetic imagery at Plateau gold deposit in Lighthouse tenements, Australia. Probe confirms gold target beyond a depth of 600 metres. Field crew now in place to prepare for start of drilling.

----------

Star Phoenix Group Ltd - oilfield services firm in Trinidad - Yet to receive outstanding USD1.5 million payment from LandOcean Energy Services Co Ltd over sale of Range Resources Trinidad Ltd. Agreed deadline for payment was Monday and Star Phoenix has made "numerous attempts" to secure cash. Company now working with legal advisers.

----------

Destiny Pharma PLC - Brighton-based biotechnology firm - Awarded grant for research with Cardiff University to assess whether its DPD‑207, XF-70 and XF-73 drug compounds can treat fungal infections. Financial terms of partnership not disclosed.

----------

PureTech Health PLC - biotherapeutics firm based in Massachusetts - Reports "positive" data from founding company Vedanta Biosciences Inc's two Phase 1 studies of VE202 candidate for inflammatory bowel disease. Study shows VE202 was "safe and well-tolerated at all doses".

----------

Hutchison China Meditech Ltd - Hong Kong-based biopharmaceutical firm - Enters into agreement with Guangzhou government for planned return of Hutchison's remaining 34 years land-use rights of about 30,000 square meters of unused site. Hutchison will secure USD95 million for the return of the site.

----------

iEnergizer Ltd - Guernsey-based IT services firm - Reports strong performance in six months to March 31, its year end date. Says focus remained on high margin work and revenue set to be in line with market expectations but earnings before interest, taxes, depreciation and amortisation beating forecasts. Reaffirms commitment for progressive dividend policy.

----------

Redcentric PLC - London-based IT services provider - Extends loan facilities until June 30, 2022. Extended loan is a GBP17.5 million revolving credit facility provided by Barclays Bank PLC and National Westminster Bank PLC.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Jul 2022 09:35

IN BRIEF: Hutchmed presents solid results from lung cancer study

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Presents positive results from the Savannah phase two trial of Hutchmed and AstraZeneca PLC's savolitinib in combination with Astra's osimertinib in epidermal growth factor receptor-mutated non-small cell lung cancer patients.

Read more
6 Jul 2022 10:37

AIM WINNERS & LOSERS: Hutchmed down amid China Covid woes; Parkmead up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
6 Jul 2022 09:25

Hutchmed phase I trial for IMG-007 doses first patient

(Alliance News) - Hutchmed China Ltd on Wednesday announced the first patient has been dosed for its phase I trial for IMG-007.

Read more
1 Jun 2022 10:07

IN BRIEF: Hutchmed China wins cancer drug Tazverik approval in Hainan

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Receives approval for Tazverik from the Health Commission & Medical Products Administration of the Hainan province in China. The approval is for use in the Hainan pilot zone under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with epithelioid sarcoma and follicular lymphoma.

Read more
3 May 2022 12:14

LONDON MARKET MIDDAY: Stocks down as aggressive US Fed rate hike looms

(Alliance News) - Stock prices in London were lower at midday on Tuesday following the long bank holiday weekend in the UK, as markets globally prepare for a sharp US interest rate hike and similar moves by other central banks as they struggle to control inflation.

Read more
3 May 2022 11:29

AIM WINNERS & LOSERS: Hutchmed sinks on US FDA drug rejection

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
3 May 2022 11:25

IN BRIEF: US FDA says Hutchmed's pancreatic drug needs more testing

Hutchmed (China) Ltd - Hong Kong-based biopharmaceuticals - The US Food & Drug Administration has rejected Hutchmed's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA says the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively. Chief Executive Officer & Chief Scientific Officer Weiguo Su comments: "Although this decision from the FDA is disappointing, we remain confident about the clinical value of surufatinib for NET patients and committed to making surufatinib available to patients globally. We look forward to working with the agency to evaluate its feedback."

Read more
3 May 2022 08:57

LONDON MARKET OPEN: BP rises despite taking hit from Rosneft exit

(Alliance News) - Stock prices in London opened lower on Tuesday following the long bank holiday weekend, with BP shares rising as the oil major planned to return cash to shareholders amid calls by some UK politicians for a windfall profit tax on energy companies.

Read more
3 May 2022 07:53

LONDON MARKET PRE-OPEN: BP swings to quarterly loss after Rosneft exit

(Alliance News) - Stock prices in London are seen opening lower on Tuesday, after the long bank holiday weekend in the UK, as concerns rise over aggressive monetary policy tightening by the US Federal Reserve.

Read more
25 Apr 2022 10:45

AIM WINNERS & LOSERS: musicMagpie sells on new platform; Hutchmed down

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
20 Apr 2022 16:05

UK shareholder meetings calendar - next 7 days

Thursday 21 April 
Alliance Trust PLCAGM
Ibstock PLCAGM
Journeo PLCAGM
Relx PLCAGM
STV Group PLCAGM
Ruffer Investment Co LtdEGM re share issue
Friday 22 April 
Bellevue Healthcare Trust PLCAGM
Faron Pharmaceuticals LtdAGM
Murray International Trust PLCAGM
Monday 25 April 
Belluscura PLCAGM
Capital Gearing Trust PLCGM re non pre-emptive share issue
Cloudbreak Discovery PLCGM re Crescita equity drawdown agreement
Hikma Pharmaceuticals PLCAGM
JPMorgan US Smaller Cos Investment Trust PLCAGM
Polymetal International PLCAGM
Symphony International Holdings LtdAGM
Tuesday 26 April 
Aquis Exchange PLCAGM
Elementis PLCAGM
GlobalData PLCAGM
Oriole Resources PLCAGM
RPS Group PLCAGM
SigmaRoc PLCAGM
Taylor Wimpey PLCAGM
Tissue Regenix Group PLCAGM
Wednesday 27 April 
Drax Group PLCAGM
EP Global Opportunities Trust PLCAGM
Global Invacom Group LtdAGM
Hutchmed (China) LtdAGM
London Stock Exchange Group PLCAGM
McKay Securities PLCGM re Workspace offer
Nichols PLCAGM
Persimmon PLCAGM
Primary Health Properties PLCAGM
VH Global Sustainable Energy Opportunities PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
31 Mar 2022 10:43

IN BRIEF: Hutchmed China named by SEC, might delist Nasdaq shares

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - US Securities & Exchange Commission identifies Hutchmed China under the new Holding Foreign Companies Accountable Act, which identifies public companies who have used auditors from overseas or auditors who are unable to be investigated completely. The new regulation has no impact on business operations, Hutchmed says.

Read more
31 Mar 2022 10:04

Hutchmed China confident after being added to SEC list

(Sharecast News) - Hutchmed China updated the market on its status under the United States 'Holding Foreign Companies Accountable Act' on Thursday.

Read more
11 Mar 2022 11:15

AIM WINNERS & LOSERS: Omega Diagnostics Visitect not available in UK

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
11 Mar 2022 10:38

IN BRIEF: Hutchmed China shares fall as US listing under threat

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Says its depositary shares may be delisted from New York's Nasdaq exchange in early 2024 unless the Holding Foreign Companies Accountable Act is amended to exclude Hutchmed. The act is part of regulatory focus in the US on access to audit and other information. It requires the US Securities & Exchange Commission to prohibit the securities of any company from being traded on any of the US securities exchanges if the auditor of the company's financial statements is not subject to inspection by the US Public Co Accounting Oversight Board for three consecutive years. Another way for Hutchmed to be excluded from the act is if the PCAOB is able to conduct a full inspection of the company's auditor during the required timeframe.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.